Recently, a series of studies linked AXL to several receptor tyrosine kinase inhibitors including EGFR inhibitors in lung cancer [70], head and neck cancer [71] and colorectal cancer [72], HER2 inhibitors in breast cancer [73], and FLT3 inhibitors in AML [74]. Here, AXL is linked to head and neck cancer.